Publications by authors named "Cassio Murilo Hidalgo Filho"
Importance: Only a small fraction of patients with advanced non-small cell lung cancer (NSCLC) respond to immune checkpoint inhibitor (ICI) treatment. For optimal personalized NSCLC care, it is imperative to identify patients who are most likely to benefit from immunotherapy.
Objective: To develop a supervised deep learning-based ICI response prediction method; evaluate its performance alongside other known predictive biomarkers; and assess its association with clinical outcomes in patients with advanced NSCLC.
Article Synopsis
- The study investigates the response to first-line PD-1 inhibitors, pembrolizumab and cemiplimab, in patients with metastatic NSCLC, focusing on those with different PD-L1 tumor proportion scores (TPS).
- It compares survival rates between patients with a PD-L1 TPS of 90% or higher and those with a score of 50% to 89%, finding significantly better outcomes for the higher TPS group in both treatment cohorts.
- Genomic profiling identified specific mutations more prevalent in lower PD-L1 expression tumors, highlighting key biological differences that may influence treatment responses.
Purpose: Most patients with cancer will be hospitalized throughout the disease course. However, most evidence on the causes and outcomes of these hospitalizations comes from administrative data or small retrospective studies from high-income countries.
Methods: This study is a retrospective cohort of patients with solid tumors hospitalized from February 1, 2021, to December 31, 2021, in a tertiary cancer center in São Paulo, Brazil.
High Dose Chemotherapy With Autologous Stem Cell Transplant for Patients With Advanced Germ Cell Tumors: Real-World Evidence From a Tertiary Cancer Center in Brazil.
Clin Genitourin Cancer
June 2024
Background: High-dose chemotherapy followed by stem cell transplant (HDCT) is potentially curative for patients with refractory germ cell tumors (rGCT). There is scarce real-world data supporting its implementation in low- and middle-income countries. We described the experience of our tertiary cancer center in Sao Paulo, Brazil.
View Article and Find Full Text PDFArticle Synopsis
- The study evaluates the effectiveness of capecitabine in treating central nervous system (CNS) metastases in breast cancer patients, highlighting its role as a common treatment choice despite limited supporting data.
- In a retrospective cohort of 209 patients, the researchers found a 3-month intracranial objective response rate (CNS-ORR) of 41.6% and a disease control rate (CNS-DCR) of 81.2%, with triple-negative breast cancer showing notably higher response rates.
- However, the study reveals a poor overall prognosis for these patients, particularly for those with triple-negative breast cancer, who had shorter progression-free survival (PFS) and overall survival (OS) compared to